{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Vlasakova K"],"funding":["Innovative Medicines Initiative"],"pagination":["769-785"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9968696"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["97(3)"],"pubmed_abstract":["Drug-induced pancreatic injury (DIPI) is an issue seen in drug development both in nonclinical and clinical contexts. DIPI is typically monitored by measurement of lipase and/or amylase, however, both enzymes lack sensitivity and specificity. Although candidate protein biomarkers specific to pancreas exist, antibody-based assay development is difficult due to their small size or the rapid cleavage by proteolytic enzymes released during pancreatic injury. Here we report the development of a novel multiplexed immunoaffinity-based liquid chromatography mass spectrometric assay (IA-LC-MS/MS) for trypsinogen activation peptide (TAP) and carboxypeptidases A1 and A2 (CPA1, CPA2). This method is based on the enzymatic digestion of the target proteins, immunoprecipitation of the peptides with speci"],"journal":["Archives of toxicology"],"pubmed_title":["Plasma biomarkers TAP, CPA1, and CPA2 for the detection of pancreatic injury in rat: the development of a novel multiplex IA-LC-MS/MS assay and biomarker performance evaluation."],"pmcid":["PMC9968696"],"funding_grant_id":["No 821283"],"pubmed_authors":["Ackermann BL","Haag H","Vlasakova K","Poetz O","Steinhilber A","Bailey WJ","Joos T","Erdos Z","Glaab WE"],"additional_accession":[]},"is_claimable":false,"name":"Plasma biomarkers TAP, CPA1, and CPA2 for the detection of pancreatic injury in rat: the development of a novel multiplex IA-LC-MS/MS assay and biomarker performance evaluation.","description":"Drug-induced pancreatic injury (DIPI) is an issue seen in drug development both in nonclinical and clinical contexts. DIPI is typically monitored by measurement of lipase and/or amylase, however, both enzymes lack sensitivity and specificity. Although candidate protein biomarkers specific to pancreas exist, antibody-based assay development is difficult due to their small size or the rapid cleavage by proteolytic enzymes released during pancreatic injury. Here we report the development of a novel multiplexed immunoaffinity-based liquid chromatography mass spectrometric assay (IA-LC-MS/MS) for trypsinogen activation peptide (TAP) and carboxypeptidases A1 and A2 (CPA1, CPA2). This method is based on the enzymatic digestion of the target proteins, immunoprecipitation of the peptides with speci","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-05-29T19:42:47.397Z","creation":"2025-05-29T19:42:47.397Z"},"accession":"S-EPMC9968696","cross_references":{"pubmed":["36481916"],"doi":["10.1007/s00204-022-03425-9"]}}